Dupilumab for prurigo nodularis: Case series and review of the literature

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Dupilumab for prurigo nodularis: Case series and review of the literature. / Holm, Jesper Gronlund; Agner, Tove; Sand, Carsten; Thomsen, Simon Francis.

I: Dermatologic Therapy, 2020.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Holm, JG, Agner, T, Sand, C & Thomsen, SF 2020, 'Dupilumab for prurigo nodularis: Case series and review of the literature', Dermatologic Therapy. https://doi.org/10.1111/dth.13222

APA

Holm, J. G., Agner, T., Sand, C., & Thomsen, S. F. (2020). Dupilumab for prurigo nodularis: Case series and review of the literature. Dermatologic Therapy, [e13222]. https://doi.org/10.1111/dth.13222

Vancouver

Holm JG, Agner T, Sand C, Thomsen SF. Dupilumab for prurigo nodularis: Case series and review of the literature. Dermatologic Therapy. 2020. e13222. https://doi.org/10.1111/dth.13222

Author

Holm, Jesper Gronlund ; Agner, Tove ; Sand, Carsten ; Thomsen, Simon Francis. / Dupilumab for prurigo nodularis: Case series and review of the literature. I: Dermatologic Therapy. 2020.

Bibtex

@article{cb77583e1eee4615ab74023f5b106663,
title = "Dupilumab for prurigo nodularis: Case series and review of the literature",
abstract = "Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.",
keywords = "anti-IL-4, biologics, dupilumab, prurigo nodularis",
author = "Holm, {Jesper Gronlund} and Tove Agner and Carsten Sand and Thomsen, {Simon Francis}",
year = "2020",
doi = "10.1111/dth.13222",
language = "English",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Dupilumab for prurigo nodularis: Case series and review of the literature

AU - Holm, Jesper Gronlund

AU - Agner, Tove

AU - Sand, Carsten

AU - Thomsen, Simon Francis

PY - 2020

Y1 - 2020

N2 - Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.

AB - Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.

KW - anti-IL-4

KW - biologics

KW - dupilumab

KW - prurigo nodularis

U2 - 10.1111/dth.13222

DO - 10.1111/dth.13222

M3 - Review

C2 - 31917498

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

M1 - e13222

ER -

ID: 237323748